glucose lowering for cardiovascular prevention

     

pathologytreatmentpatient Demonstrated benefit and harm k      
diabetes type 2aleglitazarnot classified

versus placebo

No demonstrated result for efficacy

2 trialsmeta-analysis
diabetes type 2alogliptinnot classified

versus placebo

No demonstrated result for efficacy

1 trialmeta-analysis
diabetes type 2canagliflozinnot classified

versus placebo

canagliflozin superior to placebo in terms of CV events in CANVAS, 2017

canagliflozin inferior to placebo in terms of amputation in CANVAS, 2017

1 trialmeta-analysis
diabetes type 2dapagliflozinnot classified

versus placebo

No demonstrated result for efficacy

1 trialmeta-analysis
diabetes type 2empagliflozinnot classified

versus placebo

empagliflozin superior to placebo in terms of CV events in EMPA-REG OUTCOME, 2015

1 trialmeta-analysis
diabetes type 2exenatidenot classified

versus placebo

exenatide superior to placebo in terms of CV events in EXSCEL, 2017

1 trialmeta-analysis
diabetes type 2glarginenot classified

versus

No demonstrated result for efficacy

1 trialmeta-analysis
diabetes type 2linagliptinnot classified

versus SU

No demonstrated result for efficacy

1 trialmeta-analysis
diabetes type 2liraglutidenot classified

versus placebo

liraglutide superior to placebo in terms of CV events in LEADER, 2016

1 trialmeta-analysis
diabetes type 2lixisenatide not classified

versus placebo

No demonstrated result for efficacy

1 trialmeta-analysis
diabetes type 2pioglitazonenot classified

versus placebo

No demonstrated result for efficacy

2 trialsmeta-analysis
diabetes type 2saxagliptinnot classified

versus placebo

No demonstrated result for efficacy

1 trialmeta-analysis
diabetes type 2semaglutidenot classified

versus placebo

semaglutide superior to placebo in terms of CV events in SUSTAIN 6, 2016

semaglutide inferior to placebo in terms of Retinopathy in SUSTAIN 6, 2016

1 trialmeta-analysis
diabetes type 2sitagliptinnot classified

versus placebo

No demonstrated result for efficacy

1 trialmeta-analysis